World J Gastroenterol. 2013 Aug 21;19(31):5029-34. doi: 10.3748/wjg.v19.i31.5029.
Gallstone disease represents an important issue in the healthcare system. The principal non-invasive non-surgical medical treatment for cholesterol gallstones is still represented by oral litholysis with bile acids. The first successful and documented dissolution of cholesterol gallstones was achieved in 1972. Since then a large number of investigators all over the world, have been dedicated in biochemical and clinical studies on ursodeoxycholic acid (UDCA), demonstrating its extreme versatility. This editorial is aimed to provide a brief review of recent developments in UDCA use, current indications for its use and, the more recent advances in understanding its effects in terms of an anti-inflammatory drug.
胆石病是医疗体系中的一个重要问题。胆固醇性胆石症的主要非侵入性非手术治疗方法仍然是口服胆酸溶石治疗。1972 年首次成功并记录了胆固醇胆石的溶解。从那时起,全世界的大量研究人员致力于研究熊去氧胆酸(UDCA)的生化和临床研究,证明其具有极高的多功能性。这篇社论旨在简要回顾 UDCA 使用的最新进展、目前的使用适应症,以及最近在理解其作为抗炎药物的作用方面的进展。